Form 4: BVF Partners L.P. and Affiliates Report Disposition of Allakos Inc. Shares Following Merger

BVF Partners L.P. and related entities report the disposition of their entire holdings in Allakos Inc. common stock due to the merger with Concentra Biosciences, LLC.

Summary

• BVF Partners L.P., along with several affiliated entities, filed a Form 4 detailing changes in beneficial ownership of Allakos Inc. securities.
• The filing indicates the disposition of all shares of Allakos Inc. common stock held by the reporting persons.
• This disposition is a result of the merger agreement between Allakos Inc., Concentra Biosciences, LLC, and Concentra Merger Sub III, Inc., effective April 1, 2025.
• The merger resulted in a cash payment of $0.33 per share of Allakos Inc. common stock.
• The reporting persons collectively owned over 10% of Allakos Inc.'s outstanding shares prior to the merger.
• The reporting persons include Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF I GP LLC, BVF II GP LLC, BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert.
• Each reporting person disclaims beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to a merger, so the sentiment is neutral. It simply reports the facts of the transaction.

Future Outlook

The document does not contain any forward-looking statements regarding the future outlook of BVF Partners or Allakos Inc.

Industry Context

This announcement reflects a completed merger transaction, which is a common occurrence in the biotechnology industry as companies seek to consolidate resources, technologies, or pipelines. The acquisition of Allakos Inc. by Concentra Biosciences, LLC suggests a strategic move by the latter to expand its portfolio or capabilities.

Stakeholder Impact

• Shareholders of Allakos Inc. received $0.33 per share as a result of the merger.
• The merger likely impacts employees of Allakos Inc., though the specifics are not detailed in this filing.

Key Dates

Keywords

Allakos Inc., BVF Partners, Merger, Disposition, Beneficial Ownership, Concentra Biosciences, Form 4, Securities Exchange Act